TY - JOUR AU - Biró, Orsolya AU - Fóthi, Ábel AU - Alasztics, Bálint AU - Nagy, Bálint AU - Orbán, Tamás I. AU - Rigó, János TI - Circulating exosomal and Argonaute-bound microRNAs in preeclampsia JF - GENE J2 - GENE VL - 692 ET - 0 PY - 2019 SP - 138 EP - 144 PG - 7 SN - 0378-1119 DO - 10.1016/j.gene.2019.01.012 UR - https://m2.mtmt.hu/api/publication/30401681 ID - 30401681 AB - Introduction microRNAs (miRNAs) play important role in the regulation of placental development, and abnormal miRNA expression is associated with preeclampsia (PE). miRNAs are released from trophoblast cells to maternal blood flow, where they are highly stable, being encapsulated inside extracellular vesicles, like exosomes or bound to Argonaute proteins. In PE, placental dysfunction leads to aberrant extracellular miRNA secretion. hsa-miR-210 is a hypoxia-sensitive miRNA found to be upregulated in PE; however, it is unknown whether it is the cause or the consequence of the disease. Objective Our aim was to analyze the expression of several miRNAs, including hsa-miR-210 in placenta, exosome and Ago-bound fractions comparing normal (N) and PE pregnancies. We performed in vitro analyses of extracellular hsa-miR-210 secretion of trophoblast cell cultures (of villous and extravillous origin) under hypoxic condition. Methods PE and N placenta samples were collected from C-sections, and blood samples were drawn from each pregnant woman in the third trimester. HTR-8 and JAR cell lines were cultured in exosome-free media and treated with hypoxia-mimetic agents. Exosome and Ago-bound fractions were isolated by membrane affinity spin column method from plasma and cell media. Short RNAs were extracted from exosomes and vesicle-free fractions, and total-RNA was isolated from the placenta samples. The RNA purity and concentration were measured by spectrophotometry. Expression analysis was carried out by qPCR with specific primers to target and reference miRNAs. Results The level of hsa-miR-210 was significantly higher in PE placentas, which could cause a minor increase of exosomal and a high elevation of Ago-bound miR-210 in circulation. Hypoxia lead to intracellular hsa-miR-210 upregulation in trophoblast cell lines. In extravillous cell (HTR-8) media, only the level of exosomal hsa-miR-210 was increased but no change in Ago-bound hsa-miR-210 level was observed. In contrast, in villous cell (JAR) media, the level of exosomal hsa-miR-210 was increased and enhanced release of Ago-bound hsa-miR-210 was also observed. Conclusion Based on our data, we postulate that in PE, exosomal hsa-miR-210 is secreted actively from the trophoblast, and by intercellular communication, it may have a role in disease etiology. In addition, there is a passive release of Ago-bound hsa-miR-210 into the circulation, which may represent by-products of cell-death and is thereby a possible consequence of the disease. LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Árpád Ferenc AU - Láng, Orsolya AU - Turiák, Lilla AU - Ács, András AU - Kőhidai, László AU - Fekete, Nóra AU - Alasztics, Bálint AU - Mészáros, Tamás AU - Buzás, Edit Irén AU - Rigó, János AU - Pállinger, Éva TI - The impact of circulating preeclampsia-associated extracellular vesicles on the migratory activity and phenotype of THP-1 monocytic cells JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 8 PY - 2018 IS - 1 PG - 12 SN - 2045-2322 DO - 10.1038/s41598-018-23706-7 UR - https://m2.mtmt.hu/api/publication/3366649 ID - 3366649 N1 - Department of Genetics Cell- and Immunobiology, Semmelweis University, Budapest, Hungary MS Proteomics Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary 1st Department of Obstetrics and Gynaecology, Semmelweis University, Budapest, Hungary Seroscience Ltd, Budapest, Hungary Nanomedicine Research and Education Center, Institute of Pathophysiology, Semmelweis University, Budapest, Hungary MTA-SE Immunoproteogenomics Extracellular Vesicle Research Group, Budapest, Hungary Cited By :22 Export Date: 3 February 2024 Correspondence Address: Kovács, Á.F.; Department of Genetics Cell- and Immunobiology, Hungary; email: kovacs.arpad@med.semmelweis-univ.hu LA - English DB - MTMT ER - TY - JOUR AU - Biró, Orsolya AU - Alasztics, Bálint AU - Molvarec, Attila AU - Joó, József Gábor AU - Nagy, Bálint AU - Rigó, János TI - Various levels of circulating exosomal total-miRNA and miR-210 hypoxamiR in different forms of pregnancy hypertension JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 10 PY - 2017 SP - 207 EP - 212 PG - 6 SN - 2210-7789 DO - 10.1016/j.preghy.2017.09.002 UR - https://m2.mtmt.hu/api/publication/3273020 ID - 3273020 AB - Introduction: Hypertension is a common complication during pregnancy, affecting 10% of pregnant women worldwide. Several microRNA (miRNA) were shown to be involved in hypertensive disorders of pregnancy. In preeclampsia (PE), placental dysfunction causes the enhanced release of extracellular vesicle-derived miRNAs. The hypoxia-sensitive hsa-mir-210 is the most common PE-associated miRNA, but its exosomal profile has not been investigated. Objectives: Our aims were to measure exosomal total-miRNA concentration and to perform expression analysis of circulating exosomal hsa-miR-210 in women affected by chronic hypertension (CHT) gestational hypertension (GHT) or PE. Materials and methods: We collected plasma samples from women with CHT, GHT, PE (moderate: mPE and severe: sPE) and from normotensive pregnancies. Exosomal miRNAs were extracted and miRNA concentration was measured. RT-PCR was carried out with hsa-miR-210-3p-specific primers and relative expression was calculated using the comparative Ct method. Results: The total-miRNA concentration was different in the disease subgroups, and was significantly higher in mPE and sPE compared to the other groups. We found a significant difference in the relative exosomal hsa-miR-210-3p expression between all hypertensive groups compared to the normotensive samples, but significant upregulation was only observed in case of mPE and sPE patients. Both the level of total-miRNA and hsa-miR-210 expression was higher in case of severe PE. Conclusions: The level of circulating exosomal total-miRNA and hsa-miR-210 was elevated in women with PE, and it was higher in the severe form. We showed that hsa-miR-210 is secreted via exosomes, which may have a role in the pathomechanism of the disease. © 2017 International Society for the Study of Hypertension in Pregnancy. LA - English DB - MTMT ER - TY - JOUR AU - Yanez-Mo, M AU - Siljander, PR AU - Andreu, Z AU - Zavec, AB AU - Borras, FE AU - Buzás, Edit Irén AU - Buzás, Krisztina AU - Casal, E AU - Cappello, F AU - Carvalho, J AU - Colas, E AU - Cordeiro-da Silva, A AU - Fais, S AU - Falcon-Perez, JM AU - Ghobrial, IM AU - Giebel, B AU - Gimona, M AU - Graner, M AU - Gursel, I AU - Gursel, M AU - Heegaard, NH AU - Hendrix, A AU - Kierulf, P AU - Kokubun, K AU - Kosanovic, M AU - Kralj-Iglic, V AU - Kramer-Albers, EM AU - Laitinen, S AU - Lasser, C AU - Lener, T AU - Ligeti, Erzsébet AU - Line, A AU - Lipps, G AU - Llorente, A AU - Lotvall, J AU - Mancek-Keber, M AU - Marcilla, A AU - Mittelbrunn, M AU - Nazarenko, I AU - Nolte-'t, Hoen EN AU - Nyman, TA AU - O'Driscoll, L AU - Olivan, M AU - Oliveira, C AU - Pállinger, Éva AU - Del Portillo, HA AU - Reventos, J AU - Rigau, M AU - Rohde, E AU - Sammar, M AU - Sanchez-Madrid, F AU - Santarem, N AU - Schallmoser, K AU - Ostenfeld, MS AU - Stoorvogel, W AU - Stukelj, R AU - Van, der Grein SG AU - Vasconcelos, MH AU - Wauben, MH AU - De Wever, O TI - Biological properties of extracellular vesicles and their physiological functions JF - JOURNAL OF EXTRACELLULAR VESICLES J2 - J EXTRACELLULAR VESICL VL - 4 PY - 2015 PG - 60 SN - 2001-3078 DO - 10.3402/jev.v4.27066 UR - https://m2.mtmt.hu/api/publication/2930099 ID - 2930099 N1 - Yanez-Mo M and Siljander PR authors have contributed equally. The rest of the authors are listed in alphabetical order. Unidad de Investigación, Hospital Sta Cristina, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departamento de Biología Molecular, UAM, Madrid, Spain Extracellular Vesicle Research, Division of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, Helsinki, Finland Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland Laboratory for Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, Slovenia IVECAT Group, 'Germans Trias i Pujol' Research Institute, Badalona, Spain Nephrology Service, 'Germans Trias i Pujol' University Hospital, Badalona, Spain Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary Faculty of Dentistry, University of Szeged, Szeged, Hungary Metabolomics Unit, CIC bioGUNE, CIBERehd, Bizkaia Technology Park, Derio, Spain Department of Experimental Biomedicine and Clinical Neuroscience, Human Anatomy Section, University of Palermo, Palermo, Italy Euro-Mediterranean Institute of Science and Technology, Palermo, Italy Instituto de Investigação e Inovação em Saú de, Universidade do Porto, Porto, Portugal Expression Regulation in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous, University of Barcelona, Barcelona, Spain IBMC, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), Rome, Italy IKERBASQUE, Basque Foundation for Science, Bilbao, Spain Dana-Farber Cancer Institute, Boston, MA, United States Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria Department of Neurosurgery, University of Colorado DenverCO, United States Department of Molecular Biology and Genetics, Thorlab-Therapeutic Oligonucleotide Research Lab, Bilkent University, Ankara, Turkey Department of Biological Sciences, Middle East Technical University, Ankara, Turkey Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, University of Southern Denmark, Odense, Denmark Analytical Protein Chemistry, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen, Denmark Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium Bood Cell Research Group, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway Department of Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, University of Belgrade, Belgrade, Serbia Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia Molecular Cell Biology and Focus Program Translational Neurosciences, University of Mainz, Mainz, Germany Research and Cell Services, Finnish Red Cross Blood Service, Helsinki, Finland Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Physiology, Semmelweis University, Budapest, Hungary Latvian Biomedical Research and Study Centre, Riga, Latvia Institute of Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway National Institute of Chemistry, Laboratory of Biotechnology, Ljubljana, Slovenia ENFIST Centre of Excellence, Ljubljana, Slovenia Departamento de Biología Celular y Parasitologia, Facultat de Farmacia, Universitat de Valencia, Valencia, Spain Department of Vascular Biology and Inflammation, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Institute for Environmental Health Sciences, Hospital Infection Control Medical Center, University of Freiburg, Freiburg im Breisgau, Germany Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands Institute of Biotechnology, University of Helsinki, Viikinkaari 1, Helsinki, Finland School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland Department of Pathology and Oncology, Faculty of Medicine, University of Porto, Porto, Portugal ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain Institució Catalana de Recerca I Estudis Avançats, Barcelona, Spain Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Institut de Recerca Biomèdica de Bellvitge, Barcelona, Spain Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel Servicio de Inmunología, Hospital de la Princesa, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departmnet of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto (FFUP), Porto, Portugal Cited By :955 Export Date: 30 August 2019 Correspondence Address: Yáñez-Mó, M.; Membrane Microdomains in Immunity Laboratory, Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa, Departamento de Biología Molecular, UAM, C/Maestro Amadeo Vives 2, edificio consultas 5a planta, Spain Chemicals/CAS: DNA, 9007-49-2; lipid, 66455-18-3; RNA, 63231-63-0 Unidad de Investigación, Hospital Sta Cristina, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departamento de Biología Molecular, UAM, Madrid, Spain Extracellular Vesicle Research, Division of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, Helsinki, Finland Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland Laboratory for Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, Slovenia IVECAT Group, 'Germans Trias i Pujol' Research Institute, Badalona, Spain Nephrology Service, 'Germans Trias i Pujol' University Hospital, Badalona, Spain Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary Faculty of Dentistry, University of Szeged, Szeged, Hungary Metabolomics Unit, CIC bioGUNE, CIBERehd, Bizkaia Technology Park, Derio, Spain Department of Experimental Biomedicine and Clinical Neuroscience, Human Anatomy Section, University of Palermo, Palermo, Italy Euro-Mediterranean Institute of Science and Technology, Palermo, Italy Instituto de Investigação e Inovação em Saú de, Universidade do Porto, Porto, Portugal Expression Regulation in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous, University of Barcelona, Barcelona, Spain IBMC, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), Rome, Italy IKERBASQUE, Basque Foundation for Science, Bilbao, Spain Dana-Farber Cancer Institute, Boston, MA, United States Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria Department of Neurosurgery, University of Colorado DenverCO, United States Department of Molecular Biology and Genetics, Thorlab-Therapeutic Oligonucleotide Research Lab, Bilkent University, Ankara, Turkey Department of Biological Sciences, Middle East Technical University, Ankara, Turkey Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, University of Southern Denmark, Odense, Denmark Analytical Protein Chemistry, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen, Denmark Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium Bood Cell Research Group, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway Department of Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, University of Belgrade, Belgrade, Serbia Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia Molecular Cell Biology and Focus Program Translational Neurosciences, University of Mainz, Mainz, Germany Research and Cell Services, Finnish Red Cross Blood Service, Helsinki, Finland Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Physiology, Semmelweis University, Budapest, Hungary Latvian Biomedical Research and Study Centre, Riga, Latvia Institute of Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway National Institute of Chemistry, Laboratory of Biotechnology, Ljubljana, Slovenia ENFIST Centre of Excellence, Ljubljana, Slovenia Departamento de Biología Celular y Parasitologia, Facultat de Farmacia, Universitat de Valencia, Valencia, Spain Department of Vascular Biology and Inflammation, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Institute for Environmental Health Sciences, Hospital Infection Control Medical Center, University of Freiburg, Freiburg im Breisgau, Germany Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands Institute of Biotechnology, University of Helsinki, Viikinkaari 1, Helsinki, Finland School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland Department of Pathology and Oncology, Faculty of Medicine, University of Porto, Porto, Portugal ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain Institució Catalana de Recerca I Estudis Avançats, Barcelona, Spain Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Institut de Recerca Biomèdica de Bellvitge, Barcelona, Spain Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel Servicio de Inmunología, Hospital de la Princesa, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departmnet of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto (FFUP), Porto, Portugal Cited By :1100 Export Date: 14 January 2020 Correspondence Address: Yáñez-Mó, M.; Membrane Microdomains in Immunity Laboratory, Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa, Departamento de Biología Molecular, UAM, C/Maestro Amadeo Vives 2, edificio consultas 5a planta, Spain Chemicals/CAS: DNA, 9007-49-2; lipid, 66455-18-3; RNA, 63231-63-0 Funding Agency and Grant Number: European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD) [BM1202]; ICREAICREA Funding text: The authors wish to thank Dr R Simpson and Dr D Taylor for critical reading of the manuscript and acknowledge the Horizon 2020 European Cooperation in Science and Technology programme and its support of our European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD; BM1202 www.cost.eu/COST_Actions/bmbs/Actions/BM1202) Unidad de Investigación, Hospital Sta Cristina, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departamento de Biología Molecular, UAM, Madrid, Spain Extracellular Vesicle Research, Division of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, Helsinki, Finland Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland Laboratory for Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, Slovenia IVECAT Group, 'Germans Trias i Pujol' Research Institute, Badalona, Spain Nephrology Service, 'Germans Trias i Pujol' University Hospital, Badalona, Spain Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary Faculty of Dentistry, University of Szeged, Szeged, Hungary Metabolomics Unit, CIC bioGUNE, CIBERehd, Bizkaia Technology Park, Derio, Spain Department of Experimental Biomedicine and Clinical Neuroscience, Human Anatomy Section, University of Palermo, Palermo, Italy Euro-Mediterranean Institute of Science and Technology, Palermo, Italy Instituto de Investigação e Inovação em Saú de, Universidade do Porto, Porto, Portugal Expression Regulation in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous, University of Barcelona, Barcelona, Spain IBMC, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), Rome, Italy IKERBASQUE, Basque Foundation for Science, Bilbao, Spain Dana-Farber Cancer Institute, Boston, MA, United States Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria Department of Neurosurgery, University of Colorado DenverCO, United States Department of Molecular Biology and Genetics, Thorlab-Therapeutic Oligonucleotide Research Lab, Bilkent University, Ankara, Turkey Department of Biological Sciences, Middle East Technical University, Ankara, Turkey Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, University of Southern Denmark, Odense, Denmark Analytical Protein Chemistry, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen, Denmark Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium Bood Cell Research Group, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway Department of Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, University of Belgrade, Belgrade, Serbia Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia Molecular Cell Biology and Focus Program Translational Neurosciences, University of Mainz, Mainz, Germany Research and Cell Services, Finnish Red Cross Blood Service, Helsinki, Finland Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Physiology, Semmelweis University, Budapest, Hungary Latvian Biomedical Research and Study Centre, Riga, Latvia Institute of Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway National Institute of Chemistry, Laboratory of Biotechnology, Ljubljana, Slovenia ENFIST Centre of Excellence, Ljubljana, Slovenia Departamento de Biología Celular y Parasitologia, Facultat de Farmacia, Universitat de Valencia, Valencia, Spain Department of Vascular Biology and Inflammation, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Institute for Environmental Health Sciences, Hospital Infection Control Medical Center, University of Freiburg, Freiburg im Breisgau, Germany Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands Institute of Biotechnology, University of Helsinki, Viikinkaari 1, Helsinki, Finland School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland Department of Pathology and Oncology, Faculty of Medicine, University of Porto, Porto, Portugal ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain Institució Catalana de Recerca I Estudis Avançats, Barcelona, Spain Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Institut de Recerca Biomèdica de Bellvitge, Barcelona, Spain Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel Servicio de Inmunología, Hospital de la Princesa, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departmnet of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto (FFUP), Porto, Portugal Cited By :1581 Export Date: 13 January 2021 Correspondence Address: Yáñez-Mó, M.; Membrane Microdomains in Immunity Laboratory, Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa, Departamento de Biología Molecular, UAM, C/Maestro Amadeo Vives 2, edificio consultas 5a planta, Spain Chemicals/CAS: DNA, 9007-49-2; lipid, 66455-18-3; RNA, 63231-63-0 Funding Agency and Grant Number: European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD) [BM1202]; ICREAICREA Funding Source: Custom Funding text: The authors wish to thank Dr R Simpson and Dr D Taylor for critical reading of the manuscript and acknowledge the Horizon 2020 European Cooperation in Science and Technology programme and its support of our European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD; BM1202 www.cost.eu/COST_Actions/bmbs/Actions/BM1202) AB - In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer proteins, lipids and nucleic acids, thereby influencing various physiological and pathological functions of both recipient and parent cells. While intensive investigation has targeted the role of EVs in different pathological processes, for example, in cancer and autoimmune diseases, the EV-mediated maintenance of homeostasis and the regulation of physiological functions have remained less explored. Here, we provide a comprehensive overview of the current understanding of the physiological roles of EVs, which has been written by crowd-sourcing, drawing on the unique EV expertise of academia-based scientists, clinicians and industry based in 27 European countries, the United States and Australia. This review is intended to be of relevance to both researchers already working on EV biology and to newcomers who will encounter this universal cell biological system. Therefore, here we address the molecular contents and functions of EVs in various tissues and body fluids from cell systems to organs. We also review the physiological mechanisms of EVs in bacteria, lower eukaryotes and plants to highlight the functional uniformity of this emerging communication system. LA - English DB - MTMT ER -